Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL815135 | 0.97 | CES2 (0.34) | CES2CES1GAALMNAEPHX2 | |
| SCHEMBL983977 | 0.95 | CES2 (0.36) | CES2CES1LMNAEPHX2TDP1 | |
| SCHEMBL983168 | 0.95 | CES2 (0.36) | CES2CES1LMNAEPHX2TDP1 | |
| SCHEMBL985572 | 0.95 | CES2 (0.36) | CES2CES1LMNAEPHX2TDP1 | |
| SCHEMBL981775 | 0.95 | CES2 (0.36) | CES2CES1LMNAEPHX2TDP1 | |
| SCHEMBL2973841 | 0.95 | CES2 (0.36) | CES2CES1LMNAEPHX2TDP1 | |
| SCHEMBL2975458 | 0.95 | CES2 (0.36) | CES2CES1LMNAEPHX2TDP1 | |
| SCHEMBL815041 | 0.95 | LMNA (0.33) | CES2CES1LMNATDP1 | |
| SCHEMBL816844 | 0.91 | LMNA (0.33) | CES2CES1LMNATDP1 | |
| SCHEMBL815590 | 0.91 | LMNA (0.36) | CES2CES1GAALMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2275406-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | CPS1, PHGDH, APEH | CES2 125/4885CES1 970/4885GAA 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.